Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Acute Lymphoblastic Leukemia
Promising Results for Chemotherapy-Free Induction/Consolidation Therapy in Philadelphia-Positive ALL
Patients with Philadelphia chromosome-positive ALL were treated with dasatinib and blinatumomab during induction and consolidation therapy — without chemotherapy.
Outcomes for Adolescents With Acute Lymphoblastic Leukemia
Clinical trial results indicate that adolescent patients with acute lymphoblastic leukemia have poorer outcomes than younger patients do.
Risk for Pancreatitis Greater Among Hispanic Children with Acute Lymphoblastic Leukemia
Race and ethnicity was a factor in risk for pancreatitis among children with ALL, as was age and presence of obesity and hyperglycemia.
Nelarabine for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
Genetic Predisposition for Thromboembolism in Adolescent Acute Lymphoblastic Leukemia
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
Late Morbidity, Mortality Down for Survivors of Childhood ALL
Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy.
Incorporating Immunotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia
Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.
Risk-Stratified Therapy Reduces Late Morbidity, Mortality in Pediatric Acute Lymphoblastic Leukemia
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...